The invention relates to inhibitors of Sphingosine Kinase enzymatic activity, and methods of treating diseases and disorders by administering inhibitors of Sphingosine Kinase enzymatic activity.

Polycondensation products of aminoguanidine and/or 1,3-diaminoguanidine with one or more diamines are provided including polyguanidine derivatives of the following formula (I) or a salt thereof: ##STR00001##
wherein X is selected from NH.sub.2, aminoguanidino and 1,3-diaminoguanidino; Y is selected from H and R.sub.1NH.sub.2; or X and Y together represent a chemical bond to give a cyclic structure; R.sub.1 is selected from divalent organic radicals having 2 to 20 carbon atoms, in which optionally one or more carbon atoms are replaced by O or N; a and b are each 0 or 1, wherein a+b2 if no 1,3-diaminoguanidine units are included; R.sub.2 is selected from H and NH.sub.2, wherein R.sub.2 is NH.sub.2 if a+b=0, R.sub.2 is H or NH.sub.2 if a+b=1, and R.sub.2 is H if a+b=2; and n2. Production methods and uses of the polyguanidine derivatives are also provided.

Polycondensation products of aminoguanidine and/or 1,3-diaminoguanidine with one or more diamines are provided including polyguanidine derivatives of the following formula (I) or a salt thereof: ##STR00001##
wherein X is selected from NH.sub.2, aminoguanidino and 1,3-diaminoguanidino; Y is selected from H and R.sub.1NH.sub.2; or X and Y together represent a chemical bond to give a cyclic structure; R.sub.1 is selected from divalent organic radicals having 2 to 20 carbon atoms, in which optionally one or more carbon atoms are replaced by O or N; a and b are each 0 or 1, wherein a+b2 if no 1,3-diaminoguanidine units are included; R.sub.2 is selected from H and NH.sub.2, wherein R.sub.2 is NH.sub.2 if a+b=0, R.sub.2 is H or NH.sub.2 if a+b=1, and R.sub.2 is H if a+b=2; and n2. Production methods and uses of the polyguanidine derivatives are also provided.